Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients.
cholesterol
dialysis
hyperphosphatemia
phosphate
statins
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
22
09
2021
accepted:
26
01
2022
pubmed:
4
3
2022
medline:
12
4
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
Statins are less efficacious in reducing cardiovascular disease risk in patients on dialysis than in the general population. Recent experimental data showed that phosphate excess promotes cellular In this In the AURORA trial, using multivariable analysis, we found that the treatment effect of statin on major adverse cardiovascular events and all-cause death was significant and protective effects in patients with low values of serum phosphate gradually faded for higher phosphate levels >5 mg/dl. A similar lack of statin treatment efficacy for both outcomes was observed with high baseline phosphate levels (>5 mg/dl). In the 4D trial, we found a comparable but not significant trend toward losing treatment efficacy in the presence of high serum phosphate levels for both outcomes. Our results demonstrated the limited treatment efficacy of statins in patients on dialysis in the presence of hyperphosphatemia.
Sections du résumé
BACKGROUND AND OBJECTIVES
Statins are less efficacious in reducing cardiovascular disease risk in patients on dialysis than in the general population. Recent experimental data showed that phosphate excess promotes cellular
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS
In this
RESULTS
In the AURORA trial, using multivariable analysis, we found that the treatment effect of statin on major adverse cardiovascular events and all-cause death was significant and protective effects in patients with low values of serum phosphate gradually faded for higher phosphate levels >5 mg/dl. A similar lack of statin treatment efficacy for both outcomes was observed with high baseline phosphate levels (>5 mg/dl). In the 4D trial, we found a comparable but not significant trend toward losing treatment efficacy in the presence of high serum phosphate levels for both outcomes.
CONCLUSIONS
Our results demonstrated the limited treatment efficacy of statins in patients on dialysis in the presence of hyperphosphatemia.
Identifiants
pubmed: 35236715
pii: 01277230-202204000-00012
doi: 10.2215/CJN.12620921
pmc: PMC8993469
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Phosphates
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
546-554Commentaires et corrections
Type : AssociatedDataset
Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
Massy ZA, de Zeeuw D: LDL cholesterol in CKD--To treat or not to treat? Kidney Int 84: 451–456, 2013
Shavadia JS, Wilson J, Edmonston D, Platt A, Ephraim P, Hall R, Goldstein BA, Boulware LE, Peterson E, Pendergast J, Scialla JJ: Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease. Am Heart J 231: 36–44, 2021
Drüeke TB, Massy ZA: Atherosclerosis in CKD: Differences from the general population. Nat Rev Nephrol 6: 723–735, 2010
Zhou C, He Q, Gan H, Zeng T, Liu Q, Moorhead JF, Varghese Z, Ouyang N, Ruan XZ: Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis via a mannosidases-mediated complex-type conversion of SCAP N-glycans. Kidney Int 99: 1342–1353, 2021
Hénaut L, Massy ZA: Phosphate meeting cholesterol-Consequences for cardiovascular disease in chronic kidney disease? Kidney Int 99: 1264–1267, 2021
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–1407, 2009
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248, 2005
Kuznetsova A, Brockhoff PB, Rune HBC: lmerTest: Tests in Linear Mixed Effects Models, 2020. Available at: https://CRAN.R-project.org/package=lmerTest . Accessed January 21, 2022
Bates D, Mächler M, Bolker B, Walker S: Fitting linear mixed-effects models using Lme4. J Stat Softw 67: 1–48, 2015
Harrell Jr. FE: Rms: Regression Modeling Strategies, 2019. Available at: https://hbiostat.org/R/rms/ . Accessed January 21, 2022
Proust-Lima C, Philipps V, Liquet B: Estimation of extended mixed models using latent classes and latent processes: The R Package Lcmm. J Stat Softw 78: 1–56, 2017
Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model, New York, Springer, 2000
Rader DJ: A new feature on the cholesterol-lowering landscape. Nat Med 7: 1282–1284, 2001
Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid-lowering therapy in patients with renal disease. Kidney Int 48: 188–198, 1995
Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20: 381–387, 2009
Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA: Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 20: 397–404, 2009
Gross P, Six I, Kamel S, Massy ZA: Vascular toxicity of phosphate in chronic kidney disease: Beyond vascular calcification. Circ J 78: 2339–2346, 2014